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Summary
Progressive myoclonus epilepsy of the Unverricht-Lund-
borg type (EPM1) is a rare, autosomal recessive disorder
characterized by onset at age 6–16 years, generalized
seizures, incapacitating myoclonus, and variable pro-
gression to cerebellar ataxia. The gene that causes
EPM1, cystatin B, encodes a cysteine proteinase inhib-
itor. Only a minority of EPM1 patients carry a point
mutation within the transcription unit. The majority of
EPM1 alleles contain large expansions of a dodecamer
repeat, CCC CGC CCC GCG, located upstream of the
5′ transcription start site of the cystatin B gene; normal
alleles contain two or three copies of this repeat. All
EPM1 alleles with an expansion were resistant to stan-
dard PCR amplification. To precisely determine the size
of the repeat in affected individuals, we developed a
detection protocol involving PCR amplification and sub-
sequent hybridization with an oligonucleotide contain-
ing the repeat. The largest detected expansion was ∼75
copies; the smallest was ∼30 copies. We identified af-
fected siblings with repeat expansions, of different sizes,
on the same haplotype, which confirms the repeat’s in-
stability during transmissions. Expansions were ob-
served directly; contractions were deduced by compar-
ison of allele sizes within a family. In a sample of 28
patients, we found no correlation between age at onset
of EPM1 and the size of the expanded dodecamer. This
suggests that once the dodecamer repeat expands beyond
a critical threshold, cystatin B expression is reduced in
certain cells, with pathological consequences.
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Introduction
The cystatin B gene is localized in 21q22.3 (Pennacchio
et al. 1996), and it encodes a cysteine protease inhibitor
(Turk and Bode 1991). Mutations in this gene cause
progressive myoclonus epilepsy of the Unverricht-Lund-
borg type (EPM1; MIM 254800 [http://www.ncbi.
nlm.nih.gov/omim]) (Pennacchio et al. 1996; Lafrenie`re
et al. 1997; Lalioti et al. 1997a). EPM1 is a rare, au-
tosomal recessive disease with onset at age 6–16 years.
Patients have generalized, clonic or tonic-clonic seizures
and marked progressive and incapacitating myoclonus.
They may develop ataxia and mild mental deterioration.
Only a small minority (∼14%) of the EPM1 alleles har-
bor mutations within the transcriptional unit of the gene
(Pennacchio et al. 1996; Lafrenie`re et al. 1997; Lalioti
et al. 1997a; Virtaneva et al. 1997). In the majority of
patients, the disease is associated with expansion of a
dodecamer sequence (CCC CGC CCC GCG), estimated,
by Southern blot analysis, at 160 copies (Lalioti et al.
1997b, 1997c). Normal alleles contain two or three tan-
dem copies of this sequence. Additional, rare, normal
alleles containing 12–17 repeats were identified in two
CEPH families. However, these repeats are unstably
transmitted to offspring (Lalioti et al. 1997c). The repeat
is located in the 5′ flanking region of cystatin B and
therefore, unlike the trinucleotide repeats in other re-
peat-expansion disorders, is not contained in the pri-
mary transcript (Richards and Sutherland 1992; Ashley
and Warren 1995; Paulson and Fischbeck 1996). The
expansion is associated with a marked reduction of cys-
tatin B mRNA in patients’ blood but not in their cell
lines.
Because of the nature of the repeat, which consists
only of C and G nucleotides, PCR amplification of ex-
panded EPM1 alleles of patients and heterozygotes was
not possible. To date, the expanded alleles have been
visualized only by Southern blot analysis. Because of the
limited resolution of the Southern blot, it was not pos-
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Figure 1 A, Schematic representation of exon 1 of cystatin B and the 5′ flanking region containing the dodecamer repeats. The primers
are shown as arrows below the gene. B, PCR amplification using primers 8L–17R from homozygous (lanes 1–6) and compound heterozygous
patients with two expanded alleles (lanes 7–8). C, PCR amplification from a homozygous patient (lane 1), a compound heterozygote with a
point mutation and an expansion (lane 2), a compound heterozygote with a two-nucleotide deletion and an expansion (lane 3), and normal
individuals with two and/or three copies of the repeat (lanes 4–6). The size of the normal fragment with three repeats is 482 bp. Estimated
sizes of the largest and smallest expanded alleles are indicated on the left of panels B and C.
sible to assess the instability of the large repeats, except
in an indirect manner, and then only if the differences
were substantially large (Lafrenie`re et al. 1997; Lalioti
et al. 1997c; Virtaneva et al. 1997). Moreover, the sizes
of the DNA fragments could not be determined, with
precision, to evaluate their correlation with the pheno-
type. To determine the exact sizes of alleles within a
single family, PCR amplification, with primers imme-
diately flanking the repeat, is the method of choice. We
have tried many PCR and electrophoresis conditions and
detection techniques, with the aim of consistent ampli-
fication of the repeat expansions. Here we report our
most successful procedure, which consists of a PCR am-
plification, under special conditions, and subsequent hy-
bridization of the products by use of an oligonucleotide
probe containing the repeat.
We have observed instability of the repeat, including
both expansions and contractions, between siblings who
share the same perigenic haplotype. Precise sizing of the
repeat in different individuals showed no correlation be-
tween the size of the expansion and the age at onset of
the disease.
Material and Methods
Patients
Descriptions of both the patient group and the diag-
nostic criteria have been reported elsewhere (Malafosse
et al. 1992; Lalioti et al. 1997a; R. Gouider, S. Ibrahim,
M. Fredj, R. Ouazzani, A. Gargouri, A. Malafosse, M.
Baldy-Moulinier et al., unpublished data). The study was
approved by the appropriate institutional review com-
mittees, and informed consent was obtained from the
patients and from other members of their families.
Age at onset was determined by examination of all
clinical records and detailed family history. Patients for
whom these data were not available were excluded from
the study.
PCR Amplification and Hybridization
PCR amplification of the large and normal alleles was
performed in a 15-ml volume containing 1# cloned-Pfu
polymerase buffer, 100 nM of each nucleotide (except
that 7-deaza-2′-dGTP was substituted for all dGTP), 0.5
mM of each primer, 10% dimethyl sulfoxide (DMSO),
and 1 U cloned-Pfu polymerase (Stratagene). Primers 8L
(5′-CTG CAG GAT TGC CCC TAC TCC GAC TG-3′),
17R (5′-CTG GTC GGC GAT GTG CTG GGT CTC-
3′), and 10R (5′-GGG GTC ACG TGA CGC GCG GGC
GGA ACC AAG-3′) were used. Reverse primers 10R and
17R, in combination with forward primer 8L, produced
comparable results. After the initial denaturation at
94C for 5 min, a five-cycle “touchdown” reaction (94C
for 20 s, 65Cr60C for 20 s, and 72C for 2 min) was
followed by another 25 cycles, with annealing at 60C
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Figure 2 A, Pedigree of family GVA08, from Valais, Switzerland, showing repeat instability. Affected and heterozygous individuals in the
last three generations are indicated. All EPM1 alleles share the same haplotype around cystatin B. B, PCR amplification, with primers 8L–17R,
and incorporation of a-[32P]dCTP, run on a denaturing acrylamide gel. Panel i, which shows the expanded alleles, was exposed for several days.
Panel ii, which shows normal alleles, represents a shorter exposure of a lower region of the same gel. Because of the denaturation, each allele
shows two bands. The large allele of individual V-1 (mother) has further expanded, by one repeat unit, on transmission to her carrier daughter,
VI-8. Individual VII-4 (GVA08e, table 1) has expanded allele sizes that are different from those of his affected siblings, VII-1 and VII-2 (GVA08c
and GVA08d, respectively, table 1). For each individual, the number of repeats of each allele is shown in parentheses. C, Detection of expanded
EPM1 alleles in selected affected individuals, by PCR amplification and hybridization (see Material and Methods).
and a final extension at 72C for 10 min. Products were
electrophoresed overnight, in a 2% agarose gel, and were
then transferred on a nylon hybridization filter (Zeta-
probe, Biorad). The oligonucleotide CSTB.R2, used in
hybridization, contains two copies of the dodecamer re-
peat 5′-(CCC CGC CCC GCG)2-3
′. It was labeled by use
of terminal transferase (Boehringer) and a-[32P]dATP.
Hybridization was performed in 50% formamide, 4#
SSC, 1% SDS, 10# Denhardt’s reagent, 5% dextran
sulfate, and 100 mg/ml herring sperm DNA, at 50C,
overnight. Posthybridization washes were performed
twice with 2# SSC at 50C for 30 min and then twice
with 0.1# SSC/0.1% SDS at 70C for 30 min. The filters
were exposed overnight with intensifying screens, at
80C.
For determination of the heterozygotes’ expanded al-
lele size, radioactive PCR amplification was performed
as described above, with the addition of a-[32P]dCTP.
Loading buffer, with a final concentration of 55% for-
mamide, was added, and the products were denatured
at 95C for 10 min, were loaded on a denaturing 5%
acrylamide 8M urea gel, 0.8# Tris-taurine-EDTA (20
#:1.78 M Tris base, 0.58 M taurine, 10 mM EDTA),
and were electrophoresed for 6 h at 80 W. The gel was
dried and autoradiographed for several days, at 80C.
Results and Discussion
PCR Amplification and Hybridization
Previously published PCR protocols for amplification
of CG-rich sequences, such as the fragile X alleles
(Brown et al. 1993; Chong et al. 1994; Levinson et al.
1994), failed to reproducibly amplify the EPM1 alleles.
We have tested a number of PCR conditions, varying
the DMSO concentrations, primer combinations, 7-
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Table 1
Estimates of the Number of Dodecamer Repeats in Patients with EPM1
Case
No. Patienta
Age at Onset
(years) Large Expansion Small Expansion Mean Expansion
1 GVA16 15 75 75 75
2 GVA14 13 75 54 65
3 GVA13 10 75 75 75
4 GVA15a 12 64 64 64
5 GVA15b 9 64 64 64
6 GVA15c 11 64 64 64
7 GVA11a 12 64 62 63
8 GVA11b 12 64 64 64
9 GVA11c 14 64 64 64
10 GVA24 9 63 63 63
11 GVA25a 12 60 58 59
12 GVA25b 12 58 58 58
13 GVA25c 10 58 58 58
14 GVA08a (VI-1) 13 58 55 57
15 GVA08b 14 58 55 57
16 GVA08c (VII-1) 11 59 51 55
17 GVA08d (VII-2) 14 59 51 55
18 GVA08e (VII-4) 11 58 52 56
19 GVA18 13 55 49 52
20 GVA19 9 52 30 41
21 GVA20a 10 50 50 50
22 GVA12 8 50 50 50
23 GVA17 12 50 50 50
24 GVA21b 8 50 50 50
25 GVA22 15 49 49 49
26 GVA23 14 47 47 47
27 GVA26 9 47 47 47
28 GVA27 8 46 46 46
a Numbers in parentheses represent members of the pedigree GVA08, shown in figure 2A.
deaza-2′-dGTP concentration, polymerase, and PCR
program. After PCR amplification, the products were
electrophoresed overnight, transferred, and hybridized
with an oligonucleotide primer containing two dode-
camers. The hybridization with an oligonucleotide was
preferred to direct labeling of the products by incor-
poration, because it takes advantage of the number of
repeats in the expansion to amplify the signal strength,
which would otherwise be weak because of poor am-
plification of the large alleles.
The use of Pfu polymerase, 7-deaza-2′-dGTP in place
of dGTP, and 10% DMSO resulted in the most consis-
tent amplification of the large alleles (fig. 1). The choice
of PCR program, either two-step PCR (94C and 68C)
or three-step touchdown PCR (94C, 65Cr60C, and
72C), did not affect the outcome of the reaction. How-
ever, the choice of nucleotide primers was important,
and reproducible results were obtained with the com-
binations 8L–17R and 8L–10R (fig. 1).
The amplifications from homozygous patients or from
compound heterozygous patients with two different
large alleles resulted in distinct amplified products (fig.
1B). However, in the heterozygotes with one normal and
one expanded allele, additional bands, possibly due to
heteroduplexes, were detected. Calculation of the exact
size of the large allele is difficult in such cases. Thus, for
these cases, PCR products were labeled, by incorpora-
tion of a-[32P]dCTP, and were electrophoresed in de-
naturing acrylamide gels. This method resulted in a bet-
ter estimation of the large allele size, but signal strength
was decreased (fig. 2B).
This method allowed us to calculate the sizes of the
expanded alleles with greater precision than that af-
forded by Southern blot analysis. The estimated size of
the largest allele, which was found in homozygosity, was
75 copies of the dodecamer (table 1). The smallest EPM1
allele contained 30 dodecamers and was detected in a
compound heterozygous patient who had a second allele
that contained 52 repeats.
Instability of the Expanded Alleles
The instability of alleles with 12–17 repeats (Lalioti
et al. 1997c) suggests that a similar situation may exist
for the expanded alleles. Furthermore, Southern blot
analyses of Finnish EPM1 alleles with the same haplo-
type revealed expanded alleles with different sizes, again
suggesting instability (Lafrenie`re et al. 1997; Virtaneva
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Figure 3 Plots of the age at onset of EPM1 (x axes) with the
number of dodecamer repeats (y axes) for the large, small, and mean
allele sizes.
et al. 1997). Using the PCR method described here, we
detected alleles with different numbers of repeats among
affected siblings, between parent and child, and in more
distant relatives, which directly confirms the instability
of the disease-related expansion (fig. 2). All affected in-
dividuals in the consanguineous family GVA08, shown
in figure 2, share the same haplotype around cystatin B
(data not shown). However, there are six different sizes
of expanded alleles (containing 51, 52, 55, 56, 58, and
59 repeats), all of which must have originated from a
single, ancestral expanded allele (fig. 2; table 1, family
GVA08). Because the most commonly observed allele in
the pedigree contained 55 repeats, we hypothesized that
both expansions and contractions have occurred in this
family. An alternative hypothesis might be that the an-
cestral allele contained X51 repeats and that all the
individuals in the pedigree have expanded alleles.
Another expansion has occurred in heterozygous in-
dividual VI-8. The expanded allele was transmitted from
her mother, since her normal allele, which contains two
repeats, was paternal. We have previously observed only
expansions of intermediate-sized alleles (12–13 copies of
the dodecamer) during paternal transmissions (Lalioti et
al. 1997c). The expansion of the dodecamer repeat, as
seen in individual VI-8, is the first to be associated with
maternal transmission. The PCR-amplification results
showed no evidence of substantial somatic instability of
the repeat in DNA from blood or from cell lines.
Lack of Correlation between the Expanded-Allele Size
and Age at Onset of EPM1
The age at onset of the trinucleotide-repeat–expansion
disorders often correlates with the size of the expanded
alleles (Ashley and Warren 1995; Filla et al. 1996; Paul-
son and Fischbeck 1996; Lamont et al. 1997; Monros
et al. 1997; Montermini et al. 1997). We have investi-
gated whether there is such a correlation between the
size of the dodecamer-repeat expansion in EPM1 and
the age at onset of disease. Since EPM1 is an autosomal
recessive disorder and since some of our patients were
compound heterozygotes with two different expansions,
we have examined potential associations between the
large, small, and mean allele sizes and the age at onset.
Clinical data from 28 patients were collected, and the
allele sizes were determined. As shown in figure 3, there
is no apparent correlation, in this patient group, between
the size of the repeat and the age at onset.
In Friedreich ataxia (FA), another autosomal recessive
disorder that is due to a trinucleotide-repeat expansion,
the age at onset is correlated with the size of the ex-
pansion. In compound-heterozygous FA patients with
two different expansions, the size of the smaller one was
more strongly correlated with the age at onset and the
severity of the disease (Filla et al. 1996; Lamont et al.
1997; Monros et al. 1997; Montermini et al. 1997). The
fact that this is not the case for EPM1 may suggest that
once the dodecamer repeat expands beyond a critical
threshold, cystatin B gene expression is reduced in cer-
tain cells, with pathological consequences. Therefore,
the age at onset of this disorder no longer depends on
the size of the alleles after this threshold is passed by
both alleles of a patient. This threshold is likely to be
within 13–30 copies of the dodecamer. The different ages
at onset among EPM1 siblings (table 1) could be due to
modifier genes and/or environmental factors. It is still
possible that there is correlation between EPM1 allele
size and another phenotypic determinant of the disorder.
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Detailed, standardized evaluation of phenotype is
needed to uncover such a correlation.
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